Evonik Evonik

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Acuitas","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Pfizer Enters into Agreement with Acuitas Therapeutics for Lipid Nanoparticle Delivery System for Use in mRNA Vaccines and Therapeutics","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"CANADA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2022","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed"},{"orgOrder":0,"company":"Acuitas","sponsor":"GC Biopharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"GC Biopharma Concludes Agreement With Acuitas Therapeutics for Lipid Nanoparticle Delivery System for Use in mRNA Vaccines and Therapeutics","therapeuticArea":"Technology","highestDevelopmentStatus":"Undisclosed","country":"CANADA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2022","url1":"","url2":"","graph1":"Technology","graph2":"Undisclosed"},{"orgOrder":0,"company":"Acuitas","sponsor":"Myeloid Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Myeloid Therapeutics Enters Into Agreement with Acuitas Therapeutics for Lipid Nanoparticle (LNP) System, Enabling the First-Ever Delivery of mRNA-Encoded CARs Directly to Humans","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"CANADA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling"},{"orgOrder":0,"company":"Acuitas","sponsor":"Arbor Biotechnologies, Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Arbor Biotechnologies Enters into Agreement with Acuitas Therapeutics for Lipid Nanoparticle Delivery System for Use in Rare Liver Diseases","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Undisclosed","country":"CANADA","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2022","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Undisclosed"},{"orgOrder":0,"company":"Acuitas","sponsor":"Bayer AG","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Bayer Strengthens Gene Therapy Portfolio with Lipid Nanoparticle Technology from Acuitas Therapeutics","therapeuticArea":"Technology","highestDevelopmentStatus":"Undisclosed","country":"CANADA","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2023","url1":"","url2":"","graph1":"Technology","graph2":"Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Acuitas

    Menu

    Acuitas

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Acuitas

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Canada
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Bayer Strengthens Gene Therapy Portfolio with Lipid Nanoparticle Technology from Acuitas Therapeutics

              Details:

              Acuitas’ Lipid Nanoparticle (LNP) technology will support Bayer’s in vivo gene editing and protein replacement programs with the goal of specifically delivering RNA payloads to the desired target organ, the liver.

              Lead Product(s): Undisclosed

              Therapeutic Area: Technology Product Name: Undisclosed

              Highest Development Status: Undisclosed Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Bayer AG

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement June 06, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Acuitas

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Canada
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Arbor Biotechnologies Enters into Agreement with Acuitas Therapeutics for Lipid Nanoparticle Delivery System for Use in Rare Liver Diseases

              Details:

              As part of the agreement, the companies will combine the optimized delivery of Acuitas' highly validated LNP technology with Arbor’s differentiated, proprietary CRISPR gene editing technology designed for use in vivo in patients with rare liver diseases.

              Lead Product(s): LNP-based Gene Therapy

              Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Undisclosed

              Highest Development Status: Undisclosed Product Type: Cell and Gene therapy

              Recipient: Arbor Biotechnologies, Inc

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement August 25, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Acuitas

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Canada
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Myeloid Therapeutics Enters Into Agreement with Acuitas Therapeutics for Lipid Nanoparticle (LNP) System, Enabling the First-Ever Delivery of mRNA-Encoded CARs Directly to ...

              Details:

              Through this agreement, Myeloid de-risks the development of its candidates by leveraging Acuitas’ science and proven regulatory, to rapidly translate Myeloid’s innovation to patients. The MT-301 and MT-302 programs will utilize Acuitas’ LNP deliver technology.

              Lead Product(s): MT-301

              Therapeutic Area: Oncology Product Name: MT-301

              Highest Development Status: IND Enabling Product Type: Large molecule

              Partner/Sponsor/Collaborator: Myeloid Therapeutics

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement May 19, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Acuitas

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Canada
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              GC Biopharma Concludes Agreement With Acuitas Therapeutics for Lipid Nanoparticle Delivery System for Use in mRNA Vaccines and Therapeutics

              Details:

              Under the terms of the agreement, GC Biopharma will obtain the option to license Acuitas’ LNP technology for up to four undisclosed targets, on a non-exclusive basis, for vaccine or therapeutic development.

              Lead Product(s): mRNA Vaccine

              Therapeutic Area: Technology Product Name: Undisclosed

              Highest Development Status: Undisclosed Product Type: Vaccine

              Partner/Sponsor/Collaborator: GC Biopharma

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement April 28, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Acuitas

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Canada
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Pfizer Enters into Agreement with Acuitas Therapeutics for Lipid Nanoparticle Delivery System for Use in mRNA Vaccines and Therapeutics

              Details:

              Investments will harness the power of the mRNA-LNP technology and deliver potential new breakthrough vaccines and therapeutics that address significant unmet needs for patients. This agreement expands LNP capabilities and explore more projects within existing vaccines area.

              Lead Product(s): mRNA-LNP Based Vaccine

              Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

              Highest Development Status: Undisclosed Product Type: Vaccine

              Partner/Sponsor/Collaborator: Pfizer Inc

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement January 10, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              Temad- We think of world-class quality.
              Post Enquiry
              POST ENQUIRY